Oh LOOK More Auto Immune Disorders from Covid Vaccine. Safe and Effective?
— Health Canada is updating the labels on two of the COVID-19 vaccines approved for use in Canada, to add the autoimmune disorder known as immune thrombocytopenia (ITP) as a potential side effect.
In an advisory issued Tuesday, Health Canada said it is updating the label of the Janssen (Johnson & Johnson) COVID-19 vaccine to “provide additional information about the very rare risk of ITP” and the “rare risk of venous thromboembolism (VTE)” after vaccination.
The label on the Vazxeveria vaccine made by AstraZeneca is also being updated to provide additional information about the “very rare risk” of thrombocytopenia, “including the very rare risk of ITP following vaccination,” the agency said.
The alphabet of immune disorders VITT, ITP, VTE. Not so rare when one takes this bunch of immune disorders into consideration alongside all the other ones including myocarditis/ pericarditis, bells palsy Guillaine Barre and more.
The Department is updating the label of the Janssen COVID-19 Vaccine to provide additional information about the very rare risk of immune thrombocytopenia (ITP), an autoimmune condition, and the rare risk of venous thromboembolism (VTE) following vaccination.
Health Canada is also updating the label of the Vaxzevria (AstraZeneca) COVID-19 vaccine to provide additional information about the very rare risk of thrombocytopenia, including the very rare risk of ITP, following vaccination.
- Health Canada updates Pfizer-BioNTech and Moderna COVID-19 vaccine labels to include information on myocarditis and pericarditis
- Health Canada updates Pfizer-BioNTech COVID-19 vaccine label to reflect very rare reports of Bell’s Palsy